{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:59:26Z","timestamp":1767887966171,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T00:00:00Z","timestamp":1445817600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12879-015-1183-6","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T17:48:51Z","timestamp":1445881731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Olatunji O.","family":"Adetokunboh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anel","family":"Schoonees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tolulope A.","family":"Balogun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Wiysonge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,26]]},"reference":[{"key":"1183_CR1","unstructured":"UNAIDS. The gap report. 2014. [ http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_Gap_report_en.pdf ]."},{"key":"1183_CR2","unstructured":"UNICEF. Towards an AIDS-free generation \u2013 children and AIDS: sixth stocktaking report, 2013. 2013. [ http:\/\/www.unicef.org\/gambia\/Towards_an_AIDS-free_generation_-_Children_and_AIDSSixth_Stocktaking_Report_2013.pdf ]."},{"key":"1183_CR3","unstructured":"WHO. Global update on the health sector response to HIV, 2014. 2014. [ http:\/\/apps.who.int\/iris\/bitstream\/10665\/128494\/1\/9789241507585_eng.pdf?ua=1 ]."},{"key":"1183_CR4","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013. [ http:\/\/apps.who.int\/iris\/bitstream\/10665\/85321\/1\/9789241505727_eng.pdf?ua=1 ]."},{"key":"1183_CR5","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1128\/AAC.41.5.1082","volume":"41","author":"SM Daluge","year":"1997","unstructured":"Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother. 1997;41:1082\u201393.","journal-title":"Antimicrob Agents Chemother"},{"key":"1183_CR6","unstructured":"WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2006. [ http:\/\/www.who.int\/hiv\/pub\/guidelines\/art\/en\/ ]."},{"key":"1183_CR7","unstructured":"WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. 2009. [ http:\/\/www.who.int\/hiv\/pub\/arv\/rapid_advice_art.pdf ]."},{"key":"1183_CR8","doi-asserted-by":"publisher","first-page":"F203","DOI":"10.1097\/00002030-199816000-00002","volume":"12","author":"MS Saag","year":"1998","unstructured":"Saag MS, Sonnerborg A, Torres RA, Lancaster D, Gazzard BG, Schooley RT, et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV\u2010infected adults. AIDS. 1998;12:F203\u20139.","journal-title":"AIDS"},{"key":"1183_CR9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1086\/339751","volume":"34","author":"RG Hewitt","year":"2002","unstructured":"Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34:1137\u201342.","journal-title":"Clin Infect Dis"},{"key":"1183_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1345\/aph.1K522","volume":"42","author":"CA Hughes","year":"2008","unstructured":"Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008;42:387\u201396.","journal-title":"Ann Pharmacother"},{"key":"1183_CR11","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0149-2918(02)80057-1","volume":"24","author":"PG Clay","year":"2002","unstructured":"Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther. 2002;24:1502\u201314.","journal-title":"Clin Ther"},{"key":"1183_CR12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/INF.0b013e3182076864","volume":"30","author":"P Nahirya-Ntege","year":"2011","unstructured":"Nahirya-Ntege P, Musiime V, Naidoo B, Bakeera-Kitaka S, Nathoo K, Munderi P, et al. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J. 2011;30:535\u20137.","journal-title":"Pediatr Infect Dis J"},{"key":"1183_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-3156.2010.02688.x","volume":"16","author":"P Munderi","year":"2011","unstructured":"Munderi P, Snowden WB, Walker AS, Kityo C, Mosteller M, Kabuye G, et al. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. Trop Med Int Health. 2011;16:200\u20134.","journal-title":"Trop Med Int Health"},{"key":"1183_CR14","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/INF.0b013e31828c3738","volume":"32","author":"KG Technau","year":"2013","unstructured":"Technau KG, Lazarus E, Kuhn L, Abrams EJ, Sorour G, Strehlau R, et al. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. Pediatr Infect Dis J. 2013;32:851\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"1183_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/INF.0000000000000222","volume":"33","author":"KG Technau","year":"2014","unstructured":"Technau KG, Schomaker M, Kuhn L, Moultrie H, Coovadia A, Eley B, et al. Virologic response in children treated with abacavir compared with stavudine-based antiretroviral treatment \u2013 a South African multi-cohort analysis. Pediatr Infect Dis J. 2014;33:617\u201322.","journal-title":"Pediatr Infect Dis J"},{"key":"1183_CR16","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/QAD.0b013e328347fa16","volume":"25","author":"AI Choi","year":"2011","unstructured":"Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011;25:1289\u201398.","journal-title":"AIDS"},{"key":"1183_CR17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","volume":"371","author":"CA Sabin","year":"2008","unstructured":"D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417\u201326.","journal-title":"Lancet"},{"key":"1183_CR18","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1097\/QAD.0b013e328349c6ee","volume":"25","author":"M Cruciani","year":"2011","unstructured":"Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25:1993\u20132004.","journal-title":"AIDS"},{"key":"1183_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/QAI.0b013e31826f993c","volume":"61","author":"X Ding","year":"2012","unstructured":"Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61:441\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1183_CR20","doi-asserted-by":"publisher","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","volume":"22","author":"Strategies for Management of Anti-Retroviral Therapy\/INSIGHT","year":"2008","unstructured":"Strategies for Management of Anti-Retroviral Therapy\/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17\u201324.","journal-title":"AIDS"},{"key":"1183_CR21","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1097\/QAD.0b013e32833f147f","volume":"24","author":"A Martin","year":"2010","unstructured":"Martin A, Amin J, Cooper DA, Carr A, Kelleher AD, Bloch M, et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomised clinical trial. AIDS. 2010;24:2657.","journal-title":"AIDS"},{"key":"1183_CR22","first-page":"CD008270","volume":"6","author":"M Cruciani","year":"2013","unstructured":"Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O. Abacavir based triple nucleoside regimens for maintenance therapy in patients with HIV. Cochrane Database Syst Rev. 2013;6:CD008270.","journal-title":"Cochrane Database Syst Rev"},{"key":"1183_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/2046-4053-3-87","volume":"3","author":"O Adetokunboh","year":"2014","unstructured":"Adetokunboh O, Schoonees A, Wiysonge CS. Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review protocol. Syst Rev. 2014;3:87.","journal-title":"Syst Rev"},{"key":"1183_CR24","first-page":"CD005481","volume":"3","author":"MS Shey","year":"2013","unstructured":"Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS. Cochrane Database Syst Rev. 2013;3:CD005481.","journal-title":"Cochrane Database Syst Rev"},{"key":"1183_CR25","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. www.cochrane-handbook.org ."},{"key":"1183_CR26","unstructured":"Wells, GA, Shea, B, O\u2019Connell, D, Peterson, JE, Welch, V, Losos, M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. [ http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp ]."},{"key":"1183_CR27","unstructured":"Review Manager (RevMan) [Computer program]: The Nordic Cochrane Centre. Copenhagen: The Cochrane Collaboration; 2014 [Version 5.3]."},{"key":"1183_CR28","first-page":"22","volume":"6","author":"V Musiime","year":"2014","unstructured":"Musiime V, Mulenga V, Kekitiinwa A, Cook A, Abongomera G, Thomason MJ, et al. CHAPAS 3: A randomised trial comparing stavudine vs zidovudine vs abacavir as NRTI backbone in NNRTI-based first-line ART in 478 HIV-infected children in Uganda and Zambia. Rev Antiviral Ther Infect Dis. 2014;6:22.","journal-title":"Rev Antiviral Ther Infect Dis"},{"key":"1183_CR29","unstructured":"Brennan AT, Maskew M, Long L, Sanne I, Fox MP, Conradie F. 24-month treatment outcomes amongst HIV-positive children and adolescent patients prescribed stavudine vs. abacavir. 20th International AIDS Conference, Melbourne, Australia 20 \u2013 25 July 2014. http:\/\/pag.aids2014.org\/EPosterHandler.axd?aid=2246 . Accessed 15 Aug 2014."},{"key":"1183_CR30","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:2535.","journal-title":"BMJ"},{"key":"1183_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(02)07874-1","volume":"359","author":"Paediatric European Network for Treatment of AIDS (PENTA)","year":"2002","unstructured":"Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 2002;359:733.","journal-title":"Lancet"},{"key":"1183_CR32","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/QAD.0b013e3280e087e7","volume":"21","author":"Paediatric European Network for the Treatment of AIDS (PENTA)","year":"2007","unstructured":"Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudine\/abacavir maintains virological superiority over zidovudine\/lamivudine and zidovudine\/abacavir beyond 5 years in children. AIDS. 2007;21:947\u201355.","journal-title":"AIDS"},{"key":"1183_CR33","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/INF.0000000000000308","volume":"33","author":"P Flynn","year":"2014","unstructured":"Flynn P, Komar S, Blanche S, Giaquinto C, Noguera-Julian A, Welch S, et al. Efficacy and Safety of Darunavir\/Ritonavir at 48 Weeks in Treatment-Naive, HIV-1-infected Adolescents: Results from a Phase 2 Open-label Trial (DIONE). Pediatr Infect Dis J. 2014;33:940\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"1183_CR34","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1542\/peds.103.4.e47","volume":"103","author":"MW Kline","year":"1999","unstructured":"Kline MW, Blanchard S, Fletcher CV, Shenep JL, McKinney RE, Brundage RC, et al. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. Pediatrics. 1999;103:e47.","journal-title":"Pediatrics"},{"key":"1183_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3851\/IMP2695","volume":"19","author":"V Musiime","year":"2014","unstructured":"Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, et al. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial. Antivir Ther. 2014;19:269\u201376.","journal-title":"Antivir Ther"},{"key":"1183_CR36","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1097\/INF.0b013e31828e8c09","volume":"32","author":"M Neely","year":"2013","unstructured":"Neely M, Rutstein R, Del Bianco G, Heresi G, Barton T, Wiznia A, et al. Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents. Pediatr Infect Dis J. 2013;32:e370\u20136.","journal-title":"Pediatr Infect Dis J"},{"key":"1183_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1473-3099(10)70313-3","volume":"11","author":"PENPACT-1 (PENTA 9\/PACTG 390) Study Team","year":"2011","unstructured":"PENPACT-1 (PENTA 9\/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2\/3 trial. Lancet Infect Dis. 2011;11:273.","journal-title":"Lancet Infect Dis"},{"key":"1183_CR38","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1542\/peds.107.1.e4","volume":"107","author":"X S\u00e1ez-Llorens","year":"2001","unstructured":"S\u00e1ez-Llorens X, Nelson Jr RP, Emmanuel P, Wiznia A, Mitchell C, Church JA, et al. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. Pediatrics. 2001;107:E4.","journal-title":"Pediatrics"},{"key":"1183_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1468-1293.2006.00381.x","volume":"7","author":"DM Moore","year":"2006","unstructured":"Moore DM, Hogg RS, Yip B, Wood E, Harris M, Montaner JSG. Regimen\u2010dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor\u2010based highly active antiretroviral therapy. HIV Med. 2006;7:311\u20136.","journal-title":"HIV Med"},{"key":"1183_CR40","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1468-1293.2009.00724.x","volume":"10","author":"A Hill","year":"2009","unstructured":"Hill A, Sawyer W. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first\u2010line boosted highly active antiretroviral therapy based on protease inhibitors: meta\u2010regression analysis of 12 clinical trials in 5168 patients. HIV Med. 2009;10:527\u201335.","journal-title":"HIV Med"},{"key":"1183_CR41","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1093\/jac\/dku279","volume":"69","author":"M Cruciani","year":"2014","unstructured":"Cruciani M, Mengoli C, Malena M, Serpelloni G, Parisi SG, Moyle G, et al. Virological efficacy of abacavir: systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:3169\u201380.","journal-title":"J Antimicrob Chemother"},{"key":"1183_CR42","volume-title":"Closing the quality gap: revisiting the state of the science (vol 3: quality improvement interventions to address health disparities)","author":"ML McPheeters","year":"2012","unstructured":"McPheeters ML, Kripalani S, Peterson NB, Idowu RT, Jerome RN, Potter SA, et al. Closing the quality gap: revisiting the state of the science (vol 3: quality improvement interventions to address health disparities). Rockville, MD: Agency for Healthcare Research and Quality; 2012. Evidence reports\/technology assessments, no. 208.3. AHRQ Publication No. 12-E009-EF."},{"key":"1183_CR43","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1001\/jama.285.15.2006","volume":"285","author":"D Rennie","year":"2001","unstructured":"Rennie D. CONSORT revised\u2014improving the reporting of randomized trials. JAMA. 2001;285:2006\u20137.","journal-title":"JAMA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-1183-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-015-1183-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-1183-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T09:18:00Z","timestamp":1653383880000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-015-1183-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,26]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1183"],"URL":"https:\/\/doi.org\/10.1186\/s12879-015-1183-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,26]]},"article-number":"469"}}